BioSpace News Archive

Ocular Therapeutix, Inc. announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration and other retinal diseases.

BD, a leading global medical technology company, launched BD® Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines including immunology, virology, oncology and infectious disease monitoring.

Merck, known as MSD outside of the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare.

NMD Pharma A/S announces that the U.S. Food and Drug Administration has granted orphan-drug designation for NMD670, its lead product candidate in development for treatment of myasthenia gravis.

BioRestorative Therapies, Inc. announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022.

Aquestive Therapeutics, Inc. announced positive topline results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.

Curative Biotechnology Inc. announced that it intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the Company’s proposed 1-for-400 reverse stock split.

REGENXBIO Inc. announced that it will present in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022.

The European Commission’s approval of a novel gene therapy for severe hemophilia A has paved the way for use of a companion diagnostic in the European Union.

Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced that Gilles Gallant, BPharm, PhD, FOPQ, Chief Development Officer, has received the George R. Pettit Individual Input to the Field Award for 2022.